Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind dose-finding study of VN-0200 in older Japanese adults
jRCT2071220051Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VAGA-9001a + MABH-9002b in respiratory syncytial virus disease (RSV), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Geometric mean titer of anti-RSV/A neutralizing activity on Day 57 and Geometric mean fold rise of anti-RSV/A neutralizing activity on Day 57. Started Oct 2022; status: completed.
02
Drugs
VAGA-9001a + MABH-9002b
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2071220051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220051.